Sorafenib loaded SLN magnetically targeting hepatoma

Autor: Nicoletta Depalo (a), Fabio Vischio(a), Rosa Maria Iacobazzi(e), Silvia Villa(c), Fabio Canepa(c), Elisabetta Fanizza(a,d), Valentino Laquintana(b), Maria Principia Scavo(e), Angela Lopedota(b), Annalisa Cutrignelli(b), Marinella Striccoli(a), Angela Agostiano(a,d), Massimo Franco(b), Maria Lucia Curri(a), Nunzio Denora(b)

Publikováno v: Proceeding 11th World Meeting on Pharmaceutics, Biopharmaceutics and Phamaceutical Technology, Granada-Spagna, 19-21/03/2018
info:cnr-pdr/source/autori:Nicoletta Depalo (a); Fabio Vischio(a) ; Rosa Maria Iacobazzi(e); Silvia Villa(c); Fabio Canepa(c); Elisabetta Fanizza(a,d); Valentino Laquintana(b); Maria Principia Scavo(e); Angela Lopedota(b); Annalisa Cutrignelli(b); Marinella Striccoli(a); Angela Agostiano(a,d); Massimo Franco(b); Maria Lucia Curri(a); Nunzio Denora(b)/congresso_nome:Proceeding 11th World Meeting on Pharmaceutics, Biopharmaceutics and Phamaceutical Technology/congresso_luogo:Granada-Spagna/congresso_data:19-21%2F03%2F2018/anno:2018/pagina_da:/pagina_a:/intervallo_pagine

Sorafenib, a multikinase inhibitor, has been clinically approved as the sole biological agent able to significantly improve survival in patients with advanced hepatocellular carcinoma (HCC), which are not candidates for surgical or ablative therapy.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::9b7425253a6826730b1d3eaec062afee
https://publications.cnr.it/doc/393058

Magnetically Targeted Delivery of Sorafenib to Liver Using Solid Lipid Nanoparticles for Treatment of Hepatocellular Carcinoma

Autor: Nicoletta Depalo(a), Fabio Vischio(a), Ilaria Arduino(b), Silvia Villa(c), Fabio Canepa(c), Elisabetta Fanizza(a, Byung Chul Lee(e), Valentino Laquintana(b), Angela Lopedota(b), Annalisa Cutrignelli(b), Maria Principia Scavo(f), Marinella Striccoli(a), Angela Agostiano(a, M. Lucia Curri(a), Nunzio Denora(b)

Publikováno v: ANNIC 2017, Roma, 18-20/10/2017
info:cnr-pdr/source/autori:Nicoletta Depalo(a), Fabio Vischio(a), Ilaria Arduino(b), Silvia Villa(c), Fabio Canepa(c), Elisabetta Fanizza(a,d), Byung Chul Lee(e), Valentino Laquintana(b), Angela Lopedota(b), Annalisa Cutrignelli(b), Maria Principia Scavo(f), Marinella Striccoli(a), Angela Agostiano(a,d), M. Lucia Curri(a), Nunzio Denora(b)/congresso_nome:ANNIC 2017/congresso_luogo:Roma/congresso_data:18-20%2F10%2F2017/anno:2017/pagina_da:/pagina_a:/intervallo_pagine

Advanced hepatocellular carcinoma (HCC) is a clinical challenge with limited treatment options. The orally active multikinase inhibitor sorafenib is the only anticancer agent showing a survival benefit in these patients. As well as significant activi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::16b20859bf741258d9ef62802898fddf
https://publications.cnr.it/doc/377884